Blog Big Molecule Watch November 08, 2016

PTAB Denies Institution of IPR on Humira Patent

The PTAB has denied institution of inter partes review of Abbvie’s U.S. Patent No. 9,114,166, finding that Petitioner Coherus had not established a reasonable likelihood that it would prevail in showing the unpatentability of the challenged claims.  The ‘166 patent is drawn to pharmaceutical formulations comprising an anti-TNFα antibody, and allegedly covers formulations of Humira® (adalimumab).  The IPR is docketed as IPR2016-01018.  We will continue to bring you updates on IPRs related to biologics and to post important documents on our IPR tracker page.